Clinical And Regulatory RiskFailure of clinical trials or stringent regulatory requirements may significantly impede the progress of key drug developments, potentially derailing the company's growth trajectory.
Commercialization StrategyAn untested commercialization strategy poses a substantial risk to the successful market entry and sales performance of the company's products.
Financial PerformanceDyadic's recent financial results showing a net loss could reflect underlying challenges in operational efficiency and profitability, which may concern investors about the company's fiscal health.